NCT02377401View on ClinicalTrials.gov

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

June 19, 2015

Study Completion Date

June 19, 2015

Conditions
Influenza, Human
Interventions
DRUG

Zanamivir

Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.

Trial Locations (1)

200030

GSK Investigational Site, Shanghai

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY